<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p149" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_149{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_149{left:306px;bottom:30px;}
#t3_149{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_149{left:346px;bottom:30px;}
#t5_149{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_149{left:517px;bottom:30px;}
#t7_149{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_149{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_149{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_149{left:1124px;bottom:27px;letter-spacing:0.2px;}
#tb_149{left:35px;bottom:777px;letter-spacing:0.27px;word-spacing:-0.08px;}
#tc_149{left:35px;bottom:748px;letter-spacing:0.13px;word-spacing:-0.77px;}
#td_149{left:35px;bottom:724px;letter-spacing:0.07px;word-spacing:-1.12px;}
#te_149{left:35px;bottom:701px;letter-spacing:0.08px;word-spacing:0.11px;}
#tf_149{left:35px;bottom:678px;letter-spacing:0.09px;word-spacing:0.09px;}
#tg_149{left:35px;bottom:655px;word-spacing:0.19px;}
#th_149{left:35px;bottom:616px;letter-spacing:0.04px;word-spacing:0.15px;}
#ti_149{left:35px;bottom:592px;letter-spacing:0.23px;word-spacing:-0.04px;}
#tj_149{left:35px;bottom:569px;letter-spacing:0.08px;word-spacing:0.11px;}
#tk_149{left:35px;bottom:546px;letter-spacing:0.17px;word-spacing:0.02px;}
#tl_149{left:35px;bottom:523px;letter-spacing:0.1px;}
#tm_149{left:35px;bottom:482px;letter-spacing:0.1px;word-spacing:0.09px;}
#tn_149{left:35px;bottom:459px;letter-spacing:0.1px;word-spacing:-0.66px;}
#to_149{left:35px;bottom:436px;letter-spacing:0.25px;word-spacing:-0.07px;}
#tp_149{left:35px;bottom:413px;letter-spacing:0.11px;word-spacing:0.19px;}
#tq_149{left:35px;bottom:390px;letter-spacing:0.09px;word-spacing:0.1px;}
#tr_149{left:35px;bottom:366px;letter-spacing:0.03px;word-spacing:-0.81px;}
#ts_149{left:35px;bottom:343px;letter-spacing:0.04px;word-spacing:0.15px;}
#tt_149{left:35px;bottom:320px;letter-spacing:0.24px;word-spacing:-0.05px;}
#tu_149{left:271px;bottom:327px;}
#tv_149{left:35px;bottom:281px;letter-spacing:0.15px;word-spacing:0.03px;}
#tw_149{left:35px;bottom:258px;letter-spacing:0.11px;word-spacing:-0.59px;}
#tx_149{left:35px;bottom:234px;letter-spacing:0.16px;word-spacing:0.03px;}
#ty_149{left:35px;bottom:211px;letter-spacing:0.09px;word-spacing:-0.86px;}
#tz_149{left:35px;bottom:188px;letter-spacing:0.04px;word-spacing:-0.19px;}
#t10_149{left:35px;bottom:165px;letter-spacing:0.14px;word-spacing:0.05px;}
#t11_149{left:35px;bottom:141px;letter-spacing:0.11px;word-spacing:-1.16px;}
#t12_149{left:35px;bottom:118px;letter-spacing:0.09px;word-spacing:-0.92px;}
#t13_149{left:35px;bottom:95px;letter-spacing:0.18px;word-spacing:0.01px;}
#t14_149{left:328px;bottom:103px;}
#t15_149{left:618px;bottom:777px;letter-spacing:0.07px;word-spacing:-0.43px;}
#t16_149{left:618px;bottom:754px;letter-spacing:0.14px;word-spacing:0.04px;}
#t17_149{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:-0.5px;}
#t18_149{left:618px;bottom:707px;letter-spacing:0.2px;word-spacing:-1.25px;}
#t19_149{left:911px;bottom:707px;letter-spacing:-0.07px;word-spacing:-0.97px;}
#t1a_149{left:618px;bottom:684px;letter-spacing:0.15px;word-spacing:-0.94px;}
#t1b_149{left:963px;bottom:684px;letter-spacing:0.19px;}
#t1c_149{left:618px;bottom:661px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1d_149{left:815px;bottom:668px;}
#t1e_149{left:848px;bottom:661px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1f_149{left:618px;bottom:638px;letter-spacing:0.12px;word-spacing:-0.22px;}
#t1g_149{left:618px;bottom:614px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1h_149{left:618px;bottom:591px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t1i_149{left:1115px;bottom:599px;}
#t1j_149{left:1132px;bottom:591px;letter-spacing:0.16px;}
#t1k_149{left:618px;bottom:568px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t1l_149{left:618px;bottom:545px;letter-spacing:0.12px;word-spacing:-0.8px;}
#t1m_149{left:1145px;bottom:552px;}
#t1n_149{left:618px;bottom:522px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1o_149{left:618px;bottom:498px;letter-spacing:0.02px;word-spacing:-0.79px;}
#t1p_149{left:618px;bottom:475px;letter-spacing:0.13px;word-spacing:0.19px;}
#t1q_149{left:1140px;bottom:483px;letter-spacing:0.15px;}
#t1r_149{left:618px;bottom:452px;letter-spacing:0.12px;word-spacing:0.08px;}
#t1s_149{left:618px;bottom:430px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1t_149{left:618px;bottom:407px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1u_149{left:618px;bottom:366px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1v_149{left:706px;bottom:366px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1w_149{left:915px;bottom:366px;letter-spacing:-0.02px;word-spacing:0.2px;}
#t1x_149{left:618px;bottom:343px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1y_149{left:618px;bottom:320px;letter-spacing:0.28px;word-spacing:-0.09px;}
#t1z_149{left:880px;bottom:327px;letter-spacing:0.15px;}
#t20_149{left:908px;bottom:320px;letter-spacing:0.09px;word-spacing:0.1px;}
#t21_149{left:618px;bottom:297px;letter-spacing:0.13px;word-spacing:0.05px;}
#t22_149{left:618px;bottom:273px;letter-spacing:0.08px;word-spacing:0.11px;}
#t23_149{left:618px;bottom:250px;letter-spacing:0.16px;word-spacing:0.02px;}
#t24_149{left:785px;bottom:258px;letter-spacing:0.17px;}
#t25_149{left:834px;bottom:250px;letter-spacing:-0.02px;word-spacing:0.2px;}
#t26_149{left:618px;bottom:227px;letter-spacing:0.07px;word-spacing:0.12px;}
#t27_149{left:1127px;bottom:235px;}
#t28_149{left:618px;bottom:204px;letter-spacing:0.02px;word-spacing:0.17px;}
#t29_149{left:618px;bottom:181px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2a_149{left:618px;bottom:157px;letter-spacing:0.11px;word-spacing:-1.16px;}
#t2b_149{left:1055px;bottom:165px;}
#t2c_149{left:1071px;bottom:157px;letter-spacing:-0.17px;word-spacing:-0.88px;}
#t2d_149{left:618px;bottom:134px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2e_149{left:618px;bottom:111px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2f_149{left:618px;bottom:88px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2g_149{left:618px;bottom:64px;letter-spacing:0.09px;word-spacing:-1.02px;}
#t2h_149{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_149{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_149{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_149{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_149{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_149{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_149{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_149{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_149{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts149" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg149Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg149" style="-webkit-user-select: none;"><object width="1210" height="935" data="149/149.svg" type="image/svg+xml" id="pdf149" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_149" class="t s0_149">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_149" class="t s1_149">© </span>
<span id="t3_149" class="t s0_149">(NCCN </span>
<span id="t4_149" class="t s1_149">© </span>
<span id="t5_149" class="t s0_149">), All rights reserved. NCCN Guidelines </span>
<span id="t6_149" class="t s1_149">® </span>
<span id="t7_149" class="t s0_149">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_149" class="t s2_149">NCCN Guidelines Version 4.2024 </span>
<span id="t9_149" class="t s2_149">Head and Neck Cancers </span>
<span id="ta_149" class="t s3_149">MS-8 </span>
<span id="tb_149" class="t s3_149">Short-Term Evaluation of Locoregionally Advanced Disease </span>
<span id="tc_149" class="t s4_149">Imaging is often part of response assessment following definitive therapy. </span>
<span id="td_149" class="t s4_149">Careful consideration should be given as to the type of imaging performed. </span>
<span id="te_149" class="t s4_149">It is unlikely all three modalities (CT, MRI, and FDG-PET/CT) will be </span>
<span id="tf_149" class="t s4_149">needed, and this may add cost and inconvenience without significant </span>
<span id="tg_149" class="t s4_149">added value. </span>
<span id="th_149" class="t s4_149">Patients treated with induction chemotherapy may receive imaging with </span>
<span id="ti_149" class="t s4_149">CT or MRI after two to three cycles of chemotherapy. If there is high </span>
<span id="tj_149" class="t s4_149">concern for distant metastasis, a chest CT or FDG-PET/CT may be </span>
<span id="tk_149" class="t s4_149">needed to evaluate whether to proceed to the planned definitive local </span>
<span id="tl_149" class="t s4_149">therapy. </span>
<span id="tm_149" class="t s4_149">For patients with locoregionally advanced disease who have undergone </span>
<span id="tn_149" class="t s4_149">surgery, postoperative imaging is recommended if there are signs of early </span>
<span id="to_149" class="t s4_149">recurrence or for patients considered high risk of early recurrence. This </span>
<span id="tp_149" class="t s4_149">may be needed to evaluate whether to proceed to the planned adjuvant </span>
<span id="tq_149" class="t s4_149">radiation-based therapy and/or to determine targets and dosing of </span>
<span id="tr_149" class="t s4_149">radiation in case of unexpected recurrence. Patients with positive margins, </span>
<span id="ts_149" class="t s4_149">advanced T or N stage, or oral cavity cancers are at particular risk for </span>
<span id="tt_149" class="t s4_149">rapid recurrence after surgery. </span>
<span id="tu_149" class="t s5_149">87 </span>
<span id="tv_149" class="t s4_149">After definitive-intent treatment completion, the panel generally </span>
<span id="tw_149" class="t s4_149">recommends imaging 3 to 4 months after the end of treatment, or as early </span>
<span id="tx_149" class="t s4_149">as 4 to 8 weeks after definitive treatment if there is concern about an </span>
<span id="ty_149" class="t s4_149">incomplete treatment response. Of note, proximity to recent treatment can </span>
<span id="tz_149" class="t s4_149">complicate interpretation of radiographic studies, and communication with </span>
<span id="t10_149" class="t s4_149">the interpreting radiologist is important to distinguish recurrent disease </span>
<span id="t11_149" class="t s4_149">from post-treatment effect. Positive PET results can be particularly difficult </span>
<span id="t12_149" class="t s4_149">to interpret earlier than 12 weeks following treatment, as shown in multiple </span>
<span id="t13_149" class="t s4_149">prospective and retrospective studies. </span>
<span id="t14_149" class="t s5_149">88-90 </span>
<span id="t15_149" class="t s4_149">Careful and regular follow-up examinations are recommended so that any </span>
<span id="t16_149" class="t s4_149">local or regional recurrence is detected early. After RT-based treatment, </span>
<span id="t17_149" class="t s4_149">evaluation with imaging (ie, CT and/or MRI with contrast or FDG-PET/CT) </span>
<span id="t18_149" class="t s4_149">guides the use of neck dissection (see </span><span id="t19_149" class="t s6_149">Follow-Up Recommendations: Post </span>
<span id="t1a_149" class="t s6_149">Systemic Therapy/RT or RT Neck Evaluation </span><span id="t1b_149" class="t s4_149">in the NCCN Guidelines for </span>
<span id="t1c_149" class="t s4_149">Head and Neck Cancers). </span>
<span id="t1d_149" class="t s5_149">91-95 </span>
<span id="t1e_149" class="t s4_149">A meta-analysis of 27 studies showed that </span>
<span id="t1f_149" class="t s4_149">the PPV and NPV for PET or PET/CT to detect local residual or recurrent </span>
<span id="t1g_149" class="t s4_149">disease were 52.7% and 96.3%, respectively, and 72.3% and 88.3%, </span>
<span id="t1h_149" class="t s4_149">respectively, for detection of nodal residual or recurrent disease. </span>
<span id="t1i_149" class="t s5_149">90 </span>
<span id="t1j_149" class="t s4_149">If </span>
<span id="t1k_149" class="t s4_149">PET/CT is used for follow-up, the first scan should be performed at a </span>
<span id="t1l_149" class="t s4_149">minimum of 12 weeks after treatment to reduce the false-positive rate. </span>
<span id="t1m_149" class="t s5_149">88-90 </span>
<span id="t1n_149" class="t s4_149">PET/CT surveillance in patients with advanced nodal disease who </span>
<span id="t1o_149" class="t s4_149">received systemic therapy/RT yielded a comparable survival rate and QOL </span>
<span id="t1p_149" class="t s4_149">and may be more cost-effective, relative to planned neck dissection. </span>
<span id="t1q_149" class="t s5_149">96,97 </span>
<span id="t1r_149" class="t s4_149">Care should be taken regarding the timing and interpretation of PET </span>
<span id="t1s_149" class="t s4_149">studies, as false-positive results may occur due to recent infection or </span>
<span id="t1t_149" class="t s4_149">treatment-related inflammation. </span>
<span id="t1u_149" class="t s4_149">Note that a </span><span id="t1v_149" class="t s6_149">complete clinical response </span><span id="t1w_149" class="t s4_149">(ie, clinically negative) may be </span>
<span id="t1x_149" class="t s4_149">defined as no visible or palpable evidence of residual disease and no </span>
<span id="t1y_149" class="t s4_149">concerning findings on CT or MRI </span>
<span id="t1z_149" class="t s5_149">91,98 </span>
<span id="t20_149" class="t s4_149">; a complete pathologic response </span>
<span id="t21_149" class="t s4_149">requires pathologic confirmation. If a complete clinical response to RT- </span>
<span id="t22_149" class="t s4_149">based treatment has been achieved, then the panel recommends </span>
<span id="t23_149" class="t s4_149">observing the patient. </span>
<span id="t24_149" class="t s5_149">91,98,99 </span>
<span id="t25_149" class="t s4_149">In patients who have a clinically negative </span>
<span id="t26_149" class="t s4_149">neck, PET/CT is associated with NPVs ranging from 97% to 100%. </span>
<span id="t27_149" class="t s5_149">100-102 </span>
<span id="t28_149" class="t s4_149">Panel members also concur that any patient with residual disease after </span>
<span id="t29_149" class="t s4_149">RT-based treatment should be considered for surgical resection for </span>
<span id="t2a_149" class="t s4_149">refractory disease, including a neck dissection if indicated. </span>
<span id="t2b_149" class="t s5_149">91 </span>
<span id="t2c_149" class="t s4_149">If the residual, </span>
<span id="t2d_149" class="t s4_149">persistent, or progressing disease is unresectable, then these patients </span>
<span id="t2e_149" class="t s4_149">should receive systemic therapy and/or RT as described for recurrent or </span>
<span id="t2f_149" class="t s4_149">persistent disease in the NCCN Guidelines for Head and Neck Cancers. </span>
<span id="t2g_149" class="t s4_149">For patients with equivocal PET/CT scan results in the neck, a prospective </span>
<span id="t2h_149" class="t s7_149">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
